GlassScriptPhysician profile
Fahim A Malik
NPI 1124220546
$22,472.69
in general payments reported to CMS, 2019-2025
25 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $62.51 · 2021: $124 · 2022: $832 · 2023: $2,868 · 2024: $2,461 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,129 · Food and Beverage: $5,433 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,303 · Travel and Lodging: $1,317 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,129.00 |
| Food and Beverage | $5,433.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,303.00 |
| Travel and Lodging | $1,317.10 |
| Education | $146.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $7,848.23 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $5,648.44 | 2023-2025 | |
| Lilly USA, LLC | $2,590.00 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,646.44 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $660.36 | 2021-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $569.28 | 2020-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $519.21 | 2020-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $492.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $334.03 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $303.68 | 2022-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $256.06 | 2025 | |
| Amgen INC. | $251.14 | 2019-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $222.85 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $218.04 | 2023-2025 | Ultomiris |
| Scpharmaceuticals INC. | $210.48 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $152.26 | 2025 | Ibsrela |
| Horizon Therapeutics Plc | $125.63 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $104.52 | 2023-2025 | Purified Cortrophin Gel |
| Allergan, INC. | $100.80 | 2022 | |
| Calliditas Therapeutics US INC. | $91.02 | 2022-2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $50.94 | 2023-2025 | Shingrix, Benlysta |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Philips North America LLC | $21.77 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Pfizer INC. | $13.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahim Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.